Clinical Trials on Cadonilimab

Total 7 results

Cancer Institute and Hospital, Chinese Academy...

Recruiting

NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC

Pancreatic Adenocarcinoma | Advanced Cancer | Drug Use | Capecitabine | Oxaliplatin | First-Line | Cadonilimab | Nanoliposomal Irinotecan

China
Fudan University

Recruiting

Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer

Metastatic Colorectal Cancer | Microsatellite Stable Colorectal Carcinoma | RAS Mutation | Cadonilimab

China
Shanghai Zhongshan Hospital

Recruiting

Candonilimab in Combination With LM-302 for Claudin 18.2 Positive-advanced Biliary Tract Cancer After Failure of Standard of Chemotherapy and PD1/PD-L1 Antibody

Biliary Tract Cancer | Candonilimab | Claudin 18.2

China
Peking Union Medical College Hospital

Recruiting

Cadonilimab and Lenvatinib for Conversion Therapy in Unresectable Hepatocellular Carcinoma

Cadonilimab and Lenvatinib

China
Wuhan Union Hospital, China

Recruiting

Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast Cancer

Triple-negative Breast Cancer | Cadonilimab

China
Sun Yat-sen University

Recruiting

Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases

Hepatocellular Carcinoma | Pulmonary Metastases | Bevacizumab | Liver Cancer Stage IV | Cryoablation | Cadonilimab

China
Sun Yat-sen University

Recruiting

Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC

Clear Cell Renal Cell Carcinoma | Neoadjuvant Therapy | Cadonilimab

China

Clinical Trials on Cadonilimab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo, DR of

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations